共 81 条
- [1] Gilks C.B.(2009)Ovarian carcinoma pathology and genetics: recent advances Hum Pathol 40 1213-1223
- [2] Prat J.(2003)Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 484-486
- [3] Singer G.(2005)Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis Am J Surg Pathol 29 218-224
- [4] Oldt R.(2006)The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 230-236
- [5] Cohen Y.(2007)Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 161-169
- [6] Singer G.(2004)Clinicopathological analysis of early-stage sporadic ovarian carcinoma Am J Surg Pathol 28 147-159
- [7] Stohr R.(2000)Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 564-569
- [8] Cope L.(2007)Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours J Pathol 211 286-295
- [9] Medeiros F.(2005)WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Histopathology 46 468-1329
- [10] Muto M.G.(2003)A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 1320-921